A trend observed indicated that tumors associated with poorer outcomes, such as recurrent tumors and Isocitrate Dehydrogenase (IDH) wildtype, displayed higher viability on-chip than tumors linked with improved outcomes, such as low-grade gliomas, IDH mutants, and primary tumors [233]. This evidence concerns the gene IDH1 and central nervous system cancer.